

# Dominika Anna Nowis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8497221/publications.pdf>

Version: 2024-02-01

102  
papers

7,766  
citations

126907  
33  
h-index

54911  
84  
g-index

106  
all docs

106  
docs citations

106  
times ranked

12180  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ablation of Tmcc2 Gene Impairs Erythropoiesis in Mice. International Journal of Molecular Sciences, 2022, 23, 5263.	4.1	3
2	Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma. OncolImmunology, 2021, 10, 1956143.	4.6	30
3	Tumor Immune Evasion Induced by Dysregulation of Erythroid Progenitor Cells Development. Cancers, 2021, 13, 870.	3.7	28
4	Inhibition of the $\gamma$ -glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors. Cancer Letters, 2021, 507, 13-25.	7.2	20
5	The role of CD71+ erythroid cells in the regulation of the immune response. , 2021, 228, 107927.		37
6	Mosaic <i>IL6ST</i> variant inducing constitutive GP130 cytokine receptor signaling as a cause of neonatal onset immunodeficiency with autoinflammation and dysmorphism. Human Molecular Genetics, 2021, 30, 226-233.	2.9	8
7	Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies. Cancer Research, 2021, 81, 6029-6043.	0.9	20
8	MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance. Cell Death and Disease, 2021, 12, 1111.	6.3	12
9	Potent but transient immunosuppression of T-cells is a general feature of CD71+ erythroid cells. Communications Biology, 2021, 4, 1384.	4.4	12
10	Transport of nanoprobe in multicellular spheroids. Nanoscale, 2020, 12, 19880-19887.	5.6	9
11	Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects. Cancers, 2020, 12, 2540.	3.7	36
12	Myeloid Cell-Derived Arginase in Cancer Immune Response. Frontiers in Immunology, 2020, 11, 938.	4.8	249
13	Immunoglobulin expression and the humoral immune response is regulated by the non-canonical poly(A) polymerase TENT5C. Nature Communications, 2020, 11, 2032.	12.8	34
14	The identity and methylation status of the first transcribed nucleotide in eukaryotic mRNA 5' cap modulates protein expression in living cells. Nucleic Acids Research, 2020, 48, 1607-1626.	14.5	76
15	Systematic Evaluation of Chemically Distinct Tissue Optical Clearing Techniques in Murine Lymph Nodes. Journal of Immunology, 2020, 204, 1395-1407.	0.8	10
16	Bone marrow is the preferred site of memory CD4+ T cell proliferation during recovery from sepsis. JCI Insight, 2020, 5, .	5.0	16
17	Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies. Blood, 2020, 136, 33-34.	1.4	0
18	Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nature Communications, 2019, 10, 3000.	12.8	194

#	ARTICLE	IF	CITATIONS
19	Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells. <i>Oncogene</i> , 2019, 38, 2860-2875.	5.9	19
20	Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer. <i>Annals of Agricultural and Environmental Medicine</i> , 2019, 26, 415-419.	1.0	12
21	Peroxiredoxin-5 is a negative survival predictor in ovarian cancer. <i>Ginekologia Polska</i> , 2019, 90, 1-6.	0.7	7
22	STING Signaling in Cancer Cells: Important or Not?. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2018, 66, 125-132.	2.3	56
23	Evidence of ER stress and UPR activation in patients with Brody disease and Brody syndrome. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 533-536.	3.2	1
24	Neurodevelopmental phenotype caused by a de novo <i>PTPN4</i> single nucleotide variant disrupting protein localization in neuronal dendritic spines. <i>Clinical Genetics</i> , 2018, 94, 581-585.	2.0	13
25	Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells. <i>Haematologica</i> , 2018, 103, 1843-1852.	3.5	8
26	Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis. <i>PLoS Medicine</i> , 2018, 15, e1002505.	8.4	31
27	Bortezomib-Induced Muscle Toxicity in Multiple Myeloma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 620-630.	1.7	19
28	Co-delivery of indoleamine 2,3-dioxygenase prevents loss of expression of an antigenic transgene in dystrophic mouse muscles. <i>Gene Therapy</i> , 2017, 24, 113-119.	4.5	3
29	The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma. <i>Nature Communications</i> , 2017, 8, 619.	12.8	77
30	Selection of an optimal promoter for gene transfer in normal B cells. <i>Molecular Medicine Reports</i> , 2017, 16, 3041-3048.	2.4	6
31	Development of OAT-1746, a novel arginase 1 and 2 inhibitor for cancer immunotherapy. <i>Annals of Oncology</i> , 2017, 28, v418-v419.	1.2	2
32	Abstract 3975: Ovarian cancer cells release arginase-1-containing exosomes to suppress antitumor immune response. , 2017, , .		0
33	MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. <i>PLoS ONE</i> , 2016, 11, e0155893.	2.5	26
34	Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma. <i>Oncotarget</i> , 2016, 7, 1717-1731.	1.8	48
35	Abstract 4501: Immunophenotypic identities of clinical samples have the potential to correlate with overall survival in cytogenetically normal AML patients. , 2016, , .		0
36	Abstract 5347: SK053, a small molecule inhibitor of enzymes involved in allosteric disulfide bonds formation, shows potent anti-leukemic effects and induces differentiation of human AML cells. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
37	MEK1 Inhibitor Selumetinib Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia Cells (B-ALL) to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. Blood, 2015, 126, 4917-4917.	1.4	0
38	Statins impair glucose uptake in human cells. BMJ Open Diabetes Research and Care, 2014, 2, e000017.	2.8	37
39	Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model. Translational Oncology, 2014, 7, 570-579.	3.7	17
40	Peroxiredoxin-1 protects estrogen receptor $\hat{\pm}$ from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer. Breast Cancer Research, 2014, 16, R79.	5.0	52
41	Adenanthin targets proteins involved in the regulation of disulphide bonds. Biochemical Pharmacology, 2014, 89, 210-216.	4.4	36
42	Peroxiredoxins-1 and 2 Affect Proliferation and Survival of Lymphoma Cells. Blood, 2014, 124, 1693-1693.	1.4	1
43	SK053, an Inhibitor of Enzymes Involved in Allosteric Disulfide Bonds Formation, Targets Expression of Histone Genes and Induces Differentiation of Human AML Cell. Blood, 2014, 124, 3503-3503.	1.4	0
44	GRP78-targeting subtilase cytotoxin sensitizes cancer cells to photodynamic therapy. Cell Death and Disease, 2013, 4, e741-e741.	6.3	52
45	SK053 An Inhibitor Of Enzymes Involved In Allosteric Disulfide Bonds Formation Induces Differentiation Of Human AML Cells. Blood, 2013, 122, 4215-4215.	1.4	0
46	Statins Impair Glucose Uptake in Tumor Cells. Neoplasia, 2012, 14, 311-323.	5.3	37
47	Prenyltransferases Regulate CD20 Protein Levels and Influence Anti-CD20 Monoclonal Antibody-mediated Activation of Complement-dependent Cytotoxicity. Journal of Biological Chemistry, 2012, 287, 31983-31993.	3.4	19
48	Approaches to improve photodynamic therapy of cancer. Frontiers in Bioscience - Landmark, 2011, 16, 208.	3.0	44
49	Antitumor effects of the combination of cholesterol reducing drugs. Oncology Reports, 2011, 26, 169-76.	2.6	7
50	Optimization of activation requirements of immature mouse dendritic JAWSII cells for in vivo application. Oncology Reports, 2011, 25, 831-40.	2.6	11
51	Photodynamic therapy of cancer: An update. Ca-A Cancer Journal for Clinicians, 2011, 61, 250-281.	329.8	3,902
52	PDT-induced inflammatory and host responses. Photochemical and Photobiological Sciences, 2011, 10, 653-663.	2.9	76
53	Sorafenib Affects Membrane Complement Inhibitors and Improves Antitumor Activity of Rituximab,. Blood, 2011, 118, 3723-3723.	1.4	0
54	Prenyl Transferases Are Involved in the Regulation of CD20 Levels and Influence Anti-CD20 Monoclonal Antibody-Mediated Activation of Complement-Dependent Cytotoxicity,. Blood, 2011, 118, 3722-3722.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Src Family Tyrosine Kinases Are Involved in the Transcriptional Regulation of CD20 Levels. <i>Blood</i> , 2011, 118, 1661-1661.	1.4	0
56	Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity. <i>Blood</i> , 2010, 115, 3745-3755.	1.4	40
57	Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2010, 15, 1050-1071.	4.9	253
58	Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010, 1805, 53-71.	7.4	292
59	Proteolytic pathways involved in modulation of CD20 levels. <i>Autophagy</i> , 2010, 6, 810-812.	9.1	4
60	Studies of the Synthesis of All Stereoisomers of MG-132 Proteasome Inhibitors in the Tumor Targeting Approach. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 1509-1518.	6.4	38
61	Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib. <i>American Journal of Pathology</i> , 2010, 176, 2658-2668.	3.8	115
62	Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. <i>Cancer Letters</i> , 2010, 288, 57-67.	7.2	34
63	Proteasome Inhibition Potentiates Antitumor Effects of Photodynamic Therapy in Mice through Induction of Endoplasmic Reticulum Stress and Unfolded Protein Response. <i>Cancer Research</i> , 2009, 69, 4235-4243.	0.9	96
64	Improvement of anti-tumor activity of photodynamic therapy through inhibition of cytoprotective mechanism in tumor cells. , 2009, , .		1
65	The possible role of factor H in colon cancer resistance to complement attack. <i>International Journal of Cancer</i> , 2008, 122, 2030-2037.	5.1	44
66	Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice. <i>BMC Cancer</i> , 2008, 8, 197.	2.6	59
67	Sarcolemmal Ca <sup>2+</sup> -ATPase ability to transport Ca <sup>2+</sup> gradually diminishes after myocardial infarction in the rat. <i>Cardiovascular Research</i> , 2008, 81, 546-554.	3.8	21
68	Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20. <i>PLoS Medicine</i> , 2008, 5, e64.	8.4	115
69	Ciglitazone, an agonist of peroxisome proliferator-activated receptor $\gamma$ , exerts potentiated cytostatic/cytotoxic effects against tumor cells when combined with lovastatin. <i>International Journal of Oncology</i> , 2008, , .	3.3	2
70	Ciglitazone, an agonist of peroxisome proliferator-activated receptor gamma, exerts potentiated cytostatic/cytotoxic effects against tumor cells when combined with lovastatin. <i>International Journal of Oncology</i> , 2008, 32, 249-55.	3.3	3
71	Pioglitazone, a PPAR-gamma ligand, exerts cytostatic/cytotoxic effects against cancer cells, that do not result from inhibition of proteasome. <i>Acta Biochimica Polonica</i> , 2008, 55, 75-84.	0.5	3
72	Erythropoietin reduces cisplatin-induced neurotoxicity without impairment of cytotoxic effects against tumor cells. <i>International Journal of Oncology</i> , 2007, 31, 1547-52.	3.3	3

#	ARTICLE	IF	CITATIONS
73	Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. International Journal of Oncology, 2007, , .	3.3	6
74	A novel function of VCP (valosin-containing protein; p97) in the control of N-glycosylation of proteins in the endoplasmic reticulum. Archives of Biochemistry and Biophysics, 2007, 462, 62-73.	3.0	15
75	TNF potentiates anticancer activity of bortezomib (Velcade®) through reduced expression of proteasome subunits and dysregulation of unfolded protein response. International Journal of Cancer, 2007, 121, 431-441.	5.1	26
76	Statins Impair Antitumor Effects of CD20 mAb by Inducing Conformational Changes of CD20.. Blood, 2007, 110, 2341-2341.	1.4	0
77	Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. International Journal of Oncology, 2007, 30, 1413-25.	3.3	8
78	Destabilization of the VCP-Ufd1-Npl4 complex is associated with decreased levels of ERAD substrates. Experimental Cell Research, 2006, 312, 2921-2932.	2.6	36
79	Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene, 2006, 25, 3365-3374.	5.9	163
80	Valosin-containing Protein (p97) Is a Regulator of Endoplasmic Reticulum Stress and of the Degradation of N-End Rule and Ubiquitin-Fusion Degradation Pathway Substrates in Mammalian Cells. Molecular Biology of the Cell, 2006, 17, 4606-4618.	2.1	165
81	The influence of photodynamic therapy on the immune response. Photodiagnosis and Photodynamic Therapy, 2005, 2, 283-298.	2.6	83
82	Direct tumor damage mechanisms of photodynamic therapy.. Acta Biochimica Polonica, 2005, 52, 339-352.	0.5	222
83	Direct tumor damage mechanisms of photodynamic therapy. Acta Biochimica Polonica, 2005, 52, 339-52.	0.5	63
84	CpG Immunostimulatory Oligodeoxynucleotide 1826 Enhances Antitumor Effect of Interleukin 12 Gene-Modified Tumor Vaccine in a Melanoma Model in Mice. Clinical Cancer Research, 2004, 10, 4165-4175.	7.0	35
85	Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. International Journal of Oncology, 2004, 24, 1149.	3.3	17
86	AAF-cmk sensitizes tumor cells to trail-mediated apoptosis. Leukemia Research, 2004, 28, 53-61.	0.8	4
87	Effective Photoimmunotherapy of Murine Colon Carcinoma Induced by the Combination of Photodynamic Therapy and Dendritic Cells. Clinical Cancer Research, 2004, 10, 4498-4508.	7.0	142
88	Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. International Journal of Oncology, 2004, 24, 1149-57.	3.3	20
89	Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells. Oncology Reports, 2004, 12, 1371-5.	2.6	11
90	Antitumor Effects of Photodynamic Therapy Are Potentiated by 2-Methoxyestradiol. Journal of Biological Chemistry, 2003, 278, 407-414.	3.4	113

#	ARTICLE	IF	CITATIONS
91	Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice. <i>Clinical Cancer Research</i> , 2003, 9, 5417-22.	7.0	46
92	Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice. <i>Oncology Reports</i> , 2002, 9, 199.	2.6	0
93	Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice. <i>International Journal of Cancer</i> , 2002, 97, 746-750.	5.1	16
94	Stimulation of TNF- $\beta$ production by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) - a novel immunomodulator with potential application in tumour immunotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 213-222.	2.3	4
95	Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice. <i>Oncology Reports</i> , 2002, 9, 199-203.	2.6	2
96	Antitumor activity of tributyrin in murine melanoma model. <i>Cancer Letters</i> , 2001, 164, 143-148.	7.2	16
97	In vitro antitumor activity of cerivastatin, a novel and potent HMG-CoA reductase inhibitor. <i>FEBS Letters</i> , 2001, 503, 219-220.	2.8	13
98	Butyric acid enhances in vivo expression of hTNF-alpha in transduced melanoma cell line. <i>Anticancer Research</i> , 2001, 21, 4001-4.	1.1	1
99	Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells. <i>Oncology Reports</i> , 0, , .	2.6	1
100	Rpt6. The AFCS-nature Molecule Pages, 0, , .	0.2	0
101	Rpt4. The AFCS-nature Molecule Pages, 0, , .	0.2	0
102	Rpt3. The AFCS-nature Molecule Pages, 0, , .	0.2	0